QL1206: QL1206 Denosumab injection(60 mg) was administered subcutaneously once every 6 months for a maximum of 2 consecutive doses throughout the trial.
Prolia®: Prolia® Denosumab injection(60 mg) was administered subcutaneously once every 6 months for a maximum of 2 consecutive doses throughout the trial.
Study summary
This study is a multicenter, randomized, double-blind comparative study to valuating the efficacy and safety of QL1206 and Prolia® in postmenopausal women with osteoporosis at high risk of fracture.
Eligibility
Sex
FEMALE
Min age
50 Years
Max age
85 Years
Healthy volunteers
No
Inclusion Criteria:
* Subjects who agree to participate in the study and sign the informed consent form.
* Postmenopausal women who can walk freely, aged 50-85 years (including 50 and 85 years old).
* Subjects whose absolute value of bone mineral density (BMD) in the lumbar or total hip area meets T values ≤ -2.5 and \> -4.0.
* Subjects who must have at least one of the following risk factors: History of previous fragility fractures (occurring after the age of 40); history of hip fractures in fathers or mothers; increased bone turnover rate during screening; low body weight (BMI ≤ 19 kg/m2); advanced age (aged ≥ 65 years); current smoke.
* The duration of spontaneous amenorrhea was \>2 years or \>2 years after bilateral oophorectomy. If the status of bilateral oophorectomy is unknown or if the ovaries are preserved after hysterectomy, follicle stimulating hormone (FSH) levels \>40mIU/mL may be used to confirm the status of postoperative menopause.
Exclusion Criteria:
* Bone/metabolic disease.
* Hyperparathyroidism or hypoparathyroidism.
* Thyroid condition: Hyperthyroidism or hypothyroidism.
* Rheumatoid arthritis.
* Malabsorption syndrome.
* Renal disease - severe impairment of kidney function.
* Vitamin D defViciency (25-hydroxyvitamin D, 25OHD \<20 ng/mL).
* Oral or dental diseases: previous or current evidence of mandibular osteomyelitis or osteonecrosis; Acute dental or mandibular disease requiring oral surgery; Planning invasive dental surgery; Failure to recover from dental or oral surgery.
* Previously used denosumab drugs.
* Use of intravenous bisphosphonates, fluoride, or strontium to treat osteoporosis within the last 5 years.
* OOral bisphosphonates (used for at least 3 years, or used for less than 3 years but more than 3 months, with the last use occurring \<1 year before the ICF).
* Use of any of the following drugs within 6 weeks prior to screening that may affect bone metabolism.
* History of more than two vertebral fractures.
* Malignant tumors.
Primary outcome measure(s)
Percent Change From Baseline in lumbar spine(LS)-BMD at Month 12 — Baseline and 12 months Percent Change From Baseline in lumbar spine(LS)-BMD at Month 12
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.